Literature DB >> 8659779

Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches.

I Murat1, V Billard, J Vernois, M Zaouter, P Marsol, R Souron, R Farinotti.   

Abstract

BACKGROUND: No complete pharmacokinetic profile of propofol is yet available in children younger than 3 yr, whereas clinical studies have demonstrated that both induction and maintenance doses of propofol are increased with respect to body weight in this age group compared to older children and adults. This study was therefore undertaken to determine the pharmacokinetics of propofol after administration of a single dose in aged children 1-3 yr requiring anesthesia for dressing change.
METHODS: This study was performed in 12 children admitted to the burn unit and in whom burn surface area was less than or equal to 12% of total body surface area. Exclusion criteria were: unstable hemodynamic condition, inappropriate fluid loading, associated pulmonary injury, or burn injury older than 2 days. Propofol (4 mg.kg(-1))plus fentanyl (2.5 microg.kg(-1)) was administered while the children were bathed and the burn area cleaned during which the children breathed spontaneously a mixture of oxygen and nitrous oxide (50:50). Venous blood samples of 300 microl were obtained at 5, 15, 30, 60, 90, and 120 min, and 3, 4, 8, and 12 thereafter injection; an earlier sample was obtained from 8 of 12 children. The blood concentration curves obtained for individual children were analyzed by three different methods: noncompartmental analysis, mixed effects population model, and standard two-stage analysis.
RESULTS: Using noncompartmental analysis, total clearance of propofol (+/-SD) was 0.053+/-0.013l.kg(-1).min(-1), volume of distribution at steady state9.5 +/- 3.7l.kg(-1),and residence time 188 +/- 85 min. Propofol pharmacokinetics were best described by a weight-proportional three-compartmental model in both population and two-stage analysis. Estimated and derived pharmacokinetic parameters were similar using these two pharmacokinetic approaches. Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).
CONCLUSIONS: The volume of the central compartment and the systemic clearance were both greater than all values reported in older children and adults. This is consistent with the increased propofol requirements for both induction and maintenance of anesthesia in children 1-3 yr. (Key words: Anesthesia: pediatric. Pharmacokinetics: propofol.)

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659779     DOI: 10.1097/00000542-199603000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  18 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.

Authors:  Chenguang Wang; Mariska Y M Peeters; Karel Allegaert; Heleen J Blussé van Oud-Alblas; Elke H J Krekels; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

3.  Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children.

Authors:  Byung-Moon Choi; Hyun-Gu Lee; Hyo-Jin Byon; Soo-Han Lee; Eun-Kyung Lee; Hee-Soo Kim; Gyu-Jeong Noh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-02-28       Impact factor: 2.745

Review 4.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Preliminary experience with a combination of dexmedetomidine and propofol infusions for diagnostic cardiac catheterization in children.

Authors:  Punkaj Gupta; Joseph D Tobias; Sunali Goyal; Martin D Miller; Michael M De Moor; Natan Noviski; Vipin Mehta
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

6.  Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model.

Authors:  Mariska Y M Peeters; Karel Allegaert; Heleen J Blussé van Oud-Alblas; Massimo Cella; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

Review 7.  Pharmacokinetic/pharmacodynamic modeling of anesthetics in children: therapeutic implications.

Authors:  Jean-Xavier Mazoit
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 8.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 9.  [Total intravenous anesthesia. On the way to standard practice in pediatrics].

Authors:  J M Strauss; J Giest
Journal:  Anaesthesist       Date:  2003-09       Impact factor: 1.041

10.  The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.

Authors:  Chenguang Wang; Karel Allegaert; Mariska Y M Peeters; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.